CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils
- 22 March 2007
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 81 (6) , 1374-1385
Abstract
Prion diseases are characterized by conversion of the cellular prion protein (PrPC) to a protease-resistant conformer, the srapie form of PrP (PrPSc). Humoral immune responses to nondenatured forms of PrPSc have never been fully characterized. We investigated whether production of antibodies to PrPSc could occur in PrP null (Prnp−/−) mice and further, whether innate immune stimulation with the TLR9 agonist CpG oligodeoxynucleotide (ODN) 1826 could enhance this process. Whether such stimulation could raise anti-PrPSc antibody levels in wild-type (Prnp+/+) mice was also investigated. Prnp−/− and Prnp+/+ mice were immunized with nondenatured 139A scrapie-associated fibrils (SAF), with or without ODN 1826, and were tested for titers of PrP-specific antibodies. In Prnp−/− mice, inclusion of ODN 1826 in the immunization regime increased anti-PrP titers more than 13-fold after two immunizations and induced, among others, antibodies to an N-terminal epitope, which were only present in the immune repertoire of mice receiving ODN 1826. mAb 6D11, derived from such a mouse, reacts with the N-terminal epitope QWNK in native and denatured forms of PrPSc and recombinant PrP and exhibits a Kd in the 10−11 M range. In Prnp+/+ mice, ODN 1826 increased anti-PrP levels as much as 84% after a single immunization. Thus, ODN 1826 potentiates adaptive immune responses to PrPSc in 139A SAF-immunized mice. These results represent the first characterization of humoral immune responses to nondenatured, infectious PrPSc and suggest methods for optimizing the generation of mAbs to PrPSc, many of which could be used for diagnosis and treatment of prion diseases.Keywords
Funding Information
- New York State Office of Mental Retardation and Developmental Disabilities
- National Institutes of Health (N01-NS-0-2327)
- Subcontract Principal Investigator
- Contract Principal Investigator (NS047433)
- Alzheimer’s Association/Stranahan Foundation (NIRG-04-1162)
This publication has 105 references indexed in Scilit:
- Clearance and prevention of prion infection in cell culture by anti‐PrP antibodiesEuropean Journal of Neuroscience, 2006
- Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathyVaccine, 2006
- Multiple Administrations of Oligodeoxynucleotides Containing CpG Motifs Influence Ig Isotype ProductionImmunopharmacology and Immunotoxicology, 2005
- Generation of Antibodies Against Prion Protein by Scrapie-Infected Cell Immunization of PrP 0/0 MiceHybridoma and Hybridomics, 2003
- In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversionJournal of General Virology, 2003
- Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein AntibodiesScience, 2001
- Molecular Specificities of Antibodies against Ovine and Murine Recombinant Prion ProteinsBiochemical and Biophysical Research Communications, 2001
- Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus 1 1Edited by F. CohenJournal of Molecular Biology, 2000
- New Insight into Abnormal Prion Protein Using Monoclonal AntibodiesBiochemical and Biophysical Research Communications, 1999
- Selective Oxidation of Methionine Residues in Prion ProteinsBiochemical and Biophysical Research Communications, 1999